LATEST ALERTS
Five years after German patients were first allowed to obtain medical cannabis, demand has risen sharply – but there are still some unanswered issues on policy and practice that lobbyists want addressed
Patients in Iowa who rely on supplies of medical cannabis are tightly restricted in how much they can have, and may face a long trip to get it from one of the few licensed dispensaries in the US state
The Canadian government is proposing changes to make it easier to conduct non-therapeutic cannabis research in the country and to foster more investigation into the development of cannabis products
While Big Pharma acquisitions of companies involved in the development of cannabinoid treatments are expected to to propel and expand cannabinoid treatment options, the overall impact of and interest in Big Pharma’s reach into the industry remains a matter of speculation
Scientists around the world are starting to look even further afield for potential uses of cannabis in medical applications, such as treating the symptoms of long Covid-19, Alzheimer’s-related agitation, and to alleviate the pain resulting from HIV
US firm 22nd Century Group plans to use its expertise in plant science, biotechnology and genetics to move further into cannabinoid production
This is an important year for positive legislation affecting cannabinoids across South America, though some depends on election results and all of it will take a few years to take effect
Costa Rican president Carlos Alvarado, who has supported the legalisation of cannabis throughout his administration, has partially vetoed a bill that would have legalised medicinal cannabis and industrial hemp
Research from scientists at the University of Oregon suggests that certain cannabinoids can stop the SARS-CoV-2 (Covid-19) virus from infecting cells. This may lead to future treatments
Lawsuits in the US have finally overturned the DEA’s requirement that researchers interested in studying cannabis could only purchase from one source, the University of Mississippi
Potential demand for rarer cannabinoids is prompting firms to explore other methods of manufacturing, such as biosynthesis and chemical synthesis, to give higher yields at lower cost
Colombian insurance providers must now cover the cost of medical cannabis prescriptions, a move that could represent a “billion-dollar shift” in the market – and perhaps lay down a marker for other countries
Colombia has joined a select few countries now demanding mandatory coverage of medical cannabis by health insurance providers
Desired end product and environmental factors are the two things best kept in mind when considering hemp varieties for different countries
New guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) on the use of real word data and evidence to support clinical trials could help cannabinoid products gain approval
The most common subject of recent warning letters from the US Food and Drug Administration (FDA) over unsubstantiated health claims was CBD products that were claimed to mitigate, prevent, treat, diagnose or cure Covid-19
“Intoxicating” will be the word to watch for and THC will be the main driver for developments in 2022, CBD-Intel predicts
If 2020 was the year in the waiting-room then 2021 was perhaps the year of the unfulfilled hype. As predicted, there was little movement in many of the major issues controlling the CBD market
Some sellers of intoxicating cannabinoid products claim legality under the 2018 US Farm Bill. CBD-Intel believes that many hemp-derived cannabinoids do not violate federal controlled substance law
The UK’s National Health Service (NHS) has expressed some interest in the viability of psychedelics as a course of treatment
CBD-Intel podcast editor Jon Bruford meets Dr K CBD’s Dr Ruchira Karunadasa who explains why he believes the company has an important role to play in helping the industry towards mature dialogue, and the impact that
Rahul Gupta has been confirmed by the US Senate as director of National Drug Control Policy, while president Joe Biden intends to nominate Robert Califf as head of the US Food and Drug Administration (FDA)
A research team at the University Medical Center Groningen (UMCG) in the Netherlands recently launched a three-year study into whether medicinal cannabis oil can help to regress liver-cancer tumours
Another study, this time from Italy, has found potentially dangerous levels of heavy metals and pesticides in CBD products. Researchers were worried by the results and asked regulators and legislators to act
Interest in the Brazilian medical cannabinoid market is based on optimistic projections of growth continuing in the same vein rather than concrete current numbers, a domestic report has confirmed
Interest in psychedelic drugs and treatments continues to grow, as evidenced by three major takeovers in Canada and the USA, two involving drug treatments developments and another offering a network of ketamine infusion treatment centres
It turns out the Charlotte’s Web application to the US FDA for the registration of a full spectrum hemp extract as a new dietary ingredient (NDI) DID include data from the ValidCare industry study
Two North American entrepreneurs have put millions of dollars into exploring the treatment efficacy of psychedelics, based on personal experience of using them to help deal with their own mental health issues
German imports of medical cannabis flowers rose by 80% in the first half of 2021 compared to the same period of 2021, but hopes of establishing local production were dashed
The US Drug Enforcement Agency (DEA) is calling for an increase in production of cannabis and psychedelics to supply federal research and clinical trials
NFL veteran Chris Hetherington has launched a CBD oil derived entirely from orange peel, describing it as “crystalline CBD at a purity and consistency difficult to match with cannabis or hemp-derived material”
CBD pet products remain in a grey area in terms of both legality and effectiveness – but there have been some attempts in both to shed light into the darkness
Two new studies on the biochemistry of cannabinoids could provide answers to a puzzling question – how does the entourage effect work?
A court case could force the Canadian government to process requests to use psilocybin for psychotherapeutic treatment more quickly
A recent ring trial assessment of the lab performances and methods for measuring CBD in commercial products has given some good news to the industry
A new study has shown some limited effectiveness for the use of CBD in combatting nicotine withdrawal symptoms
New methods for laboratory production of cannabinoids show some promise – but it’s still not clear whether they will yield enough to be commercially viable
Researchers at the University of San Diego in California have published a paper showing early evidence that CBD may help ease the symptoms of nicotine withdrawal
Public health insurance reimbursements and no defined list of indications for medical cannabis have helped the German medical cannabis market start to realise its massive potential
Research from a CBD watchdog firm has found considerable inconsistencies between the levels of delta-8 THC stated on product labels and what was revealed by laboratory tests
Both synthetic and plant-derived CBD degrade when stored incorrectly, producing THC, according to a new study
London-listed Kanabo has launched the first medical cannabis vaping product in the UK in a move the company’s founder hopes will ultimately revolutionise the way medicines are administered
Medical cannabis advocates are keen to see if Sajid Javid’s appointment as UK health secretary means he will continue his work from 2018, when he helped change the law on medicinal cannabis prescriptions
Stay up-to-date with key regulatory news and receive complimentary data on a regular basis.
Submit your access request to explore how it can streamlines access to critical cannabis insights
"*" indicates required fields
